Insight

Giannis Mountzios: Lorlatinib in ALK positive NSCLC sets a new benchmark in Precision Oncology

Photo taken from Giannis Mountzios/X

Jun 2, 2024, 11:16

Giannis Mountzios: Lorlatinib in ALK positive NSCLC sets a new benchmark in Precision Oncology

Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General Hospital, Athens, recently shared on X:

“For the 1st time in the history of Thoracic Oncology a molecular agent confers a median PFS exceeding 5 years in metastatic disease! Lorlatinib in ALK-positive NSCLC with the CROWN study sets a new benchmark in Precision Oncology!

Deserve to celebrate!”

Source: Giannis Mountzios/X

2024 Annual Meeting of ASCO ALK-positive NSCLC ASCO ASCO24 cancer CROWN study Giannis Mountzios lorlatinib Lung cancer NSCLC OncoDaily Oncology Precision Oncology Thoracic Oncology

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage